← Leaderboards
Lee Roy Morgan
Dekk-Tec, Inc.
$7,374,808
Attributed
$7,374,808
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $805.5K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$7,374,808 · 13
By mechanism
R44$6,048,786 · 7
R43$1,326,022 · 6
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignToxic EffectMalignant NeoplasmsPyridineResponseClinical TrialsBrain NeoplasmsAnimalsDrug KineticsPhase I Clinical TrialsCancer TherapyMonitorPharmaceutical PreparationsAdvanced Malignant NeoplasmResearch Project GrantsBlood - Brain Barrier AnatomyIrritationPhase 1 StudyBackBlood CirculationAdultChildhoodDrug Screening /EvaluationNeurotoxicity
Grant awards (26)
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies$451,382
R44 · FY2020 · CA · contact PI
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies$519,480
R44 · FY2019 · CA · contact PI
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies$240,368
R44 · FY2018 · CA · contact PI
A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS$143,294
R43 · FY2018 · CA · contact PI
A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS$143,294
R43 · FY2017 · CA · contact PI
Phase I Clinical trial with 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Children with Cancer Involving the CNS$90,362
R43 · FY2017 · CA · contact PI
The DEKK-TEC I-Corp Team$50,000
R43 · FY2017 · CA · contact PI
Phase I Clinical trial with 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Children with Cancer Involving the CNS$90,362
R43 · FY2016 · CA · contact PI
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica$522,886
R44 · FY2014 · CA · contact PI
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica$638,567
R44 · FY2013 · CA · contact PI
Camptothecin Analogs for Cancer Therapy$392,344
R44 · FY2011 · CA · contact PI
Camptothecin Analogs for Cancer Therapy$444,873
R44 · FY2010 · CA · contact PI
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr$131,674
R43 · FY2009 · CA · contact PI
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr$140,983
R43 · FY2008 · CA · contact PI
Clinical Development of 4-Hydroperoxyifosfamide$244,853
R44 · FY2007 · CA · contact PI
Camptothecin Analogs for Cancer Therapy$158,895
R43 · FY2007 · CA · contact PI
Clinical Development of 4-Hydroperoxyifosfamide$294,271
R44 · FY2006 · CA · contact PI
A-007: Immune Modulation of HPV - Associated Neoplasia$805,491
R44 · FY2005 · CA
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS$320,366
R44 · FY2003 · CA
Clinical Development of 4-Hydroperoxyifosfamide$185,641
R43 · FY2002 · CA
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS$122,592
R44 · FY2002 · CA
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS$359,498
R44 · FY2001 · CA
ISOPHOSPHORAMIDE MUSTARD--A PHASE 1 STUDY$338,965
R44 · FY2001 · CA
A-007: IMMUNE MODULATION OF HPV - CERVICAL CANCER$191,517
R43 · FY2001 · CA
ISOPHOSPHORAMIDE MUSTARD--A PHASE 1 STUDY$225,894
R44 · FY2000 · CA
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS$126,956
R44 · FY2000 · CA